Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -32M | 30.9% |
| Cost of Revenue | 31M | 30.2% |
| Operating expense | 162M | 7.9% |
| Net Income | -171M | 0.2% |
| EBITDA | -157M | 8.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.14B | 29% |
| Total Liabilities | 954M | 72.5% |
| Total Equity | 185M | 43.9% |
| Shares Outstanding | 124M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -137M | 18.9% |
| Cash from investing | -223M | 3308% |
| Cash from financing | 389M | 672.2% |
EPS
Financial Highlights for Arrowhead Pharmaceuticals in Q3 '24
Gross Profit stood at -32M, marking a -30.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 31M, a 30.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 162M, showing a -7.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -171M, showing a 0.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -157M, showing a 8.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Arrowhead Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
